To evaluate whether the tumor-suppressive effects of SNX1 could be generalized, particularly in the context of the prevalent p53-mutant high-grade serous ovarian carcinoma (HGSOC), we extended our analysis to the CAOV-3 cell line, which harbors a p53 mutation. This evidence concerns the gene TP53 and ovarian serous carcinoma.